The Efficacy of MDMA (3,4-Methylenedioxymethamphetamine) for Post-traumatic Stress Disorder in Humans: A Systematic Review and Meta-Analysis

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2021 Jun 21

PMID 34150406

Citations 14

Authors

Sarah Tedesco

Ganeya Gajaram

Shahzad Chida

Arham Ahmad

Meghan Pentak

Marina Kelada

Layth Lewis

Deepa Krishnan

Carolyn Tran

Oladipo T Soetan

Lawrance T Mukona

Ayodeji Jolayemi

Affiliations

Soon will be listed here.

Abstract

: 3,4-methylenedioxymethamphetamine (MDMA), known recreationally as "Molly" or "Ecstasy", is a triple monoamine reuptake inhibitor. MDMA specifically acts as a weak 5-HT1 and 5-HT2 receptor agonist, targeting 5-HT, 5-HT, and 5-HTreceptors. Its potential use for therapeutic purposes with these pharmacological profiles remains a controversial subject. Studies have shown the potential benefits in clinical trials for post-traumatic stress disorder (PTSD). A larger amount of data has been provided for the push in support of MDMA-assisted psychotherapy in these patients. : The aim of this article is to compute a meta-analysis and conduct a systematic review of the effects of MDMA on PTSD, discussing the potential benefits and adverse events relative to dosing and stability of treatment. : Articles were collected and analyzed for systematic review: 16 articles were included in the systematic review that met the criteria for the use of MDMA in the treatment of PTSD as well as assessing the safety and efficacy of the drug in human participants. Ten studies were used for the meta-analysis, with a cumulative sample size of 168 patients. The significance of the findings on dosing and efficacy of MDMA in healthy human participants was quantified based on the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) and PTSD symptom scores. : The disorders for which MDMA demonstrated a net positive or net negative effect on symptoms are presented separately. Adverse events in patients across all disease classes are presented. The therapeutic index for patients who demonstrated a benefit is also presented. An odds ratio for beneficial and adverse events is used to determine treatment-resistant patients who may benefit from clinical trials of MDMA. : Findings show promising evidence for the potential therapeutic use of MDMA alongside psychotherapy in the treatment of PTSD. The pharmacological profile of MDMA may provide direction for future drug developments to treat patients with treatment-resistant psychiatric disorders.

Citing Articles

Critical appraisal of evidence supporting prescription of psychedelics from clinic websites in Ontario, Canada.

Kim K, Yusuf A, Sud A, Persaud N, Kirubarajan A, Moller M PLoS One. 2024; 19(10):e0309911.

PMID: 39446753 PMC: 11500855. DOI: 10.1371/journal.pone.0309911.

MDMA-assisted psychotherapy for the treatment of PTSD: A systematic review and meta-analysis of randomized controlled trials (RCTs).

Shahrour G, Sohail K, Elrais S, Khan M, Javeid J, Samdani K Neuropsychopharmacol Rep. 2024; 44(4):672-681.

PMID: 39381877 PMC: 11609750. DOI: 10.1002/npr2.12485.

Overview of Psychiatric Medications in the Pipeline in Phase III Trials as of June 1, 2024: A Systematic Review.

IsHak W, Meyer A, Freire L, Totlani J, Murphy N, Renteria S Innov Clin Neurosci. 2024; 21(7-9):27-47.

PMID: 39329027 PMC: 11424068.

Chemical composition of Ecstasy tablets seized in Poland between 2005 and 2020.

Byrska B, Stanaszek R Forensic Toxicol. 2024; 43(1):22-32.

PMID: 39017813 DOI: 10.1007/s11419-024-00691-3.

Feasibility and effectiveness study of applying a hallucinogen harm reduction and integration model to a mindfulness thinking intervention using virtual reality: A randomized controlled trial.

Chen Y, Wang T, Tan Y, Li D Digit Health. 2024; 10:20552076241249869.

PMID: 38665888 PMC: 11044783. DOI: 10.1177/20552076241249869.

References

Mithoefer M, Feduccia A, Jerome L, Mithoefer A, Wagner M, Walsh Z . MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology (Berl). 2019; 236(9):2735-2745. PMC: 6695343. DOI: 10.1007/s00213-019-05249-5. View

Otalora G M, Grigsby J, Poulter B, Van Derveer 3rd J, Giron S, Jerome L . 3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: A randomized phase 2 controlled trial. J Psychopharmacol. 2018; 32(12):1295-1307. PMC: 6247454. DOI: 10.1177/0269881118806297. View

Corey V, Pisano V, Halpern J . Effects of 3,4-Methylenedioxymethamphetamine on Patient Utterances in a Psychotherapeutic Setting. J Nerv Ment Dis. 2016; 204(7):519-23. DOI: 10.1097/NMD.0000000000000499. View

Esber G, Roesch M, Bali S, Trageser J, Bissonette G, Puche A . Attention-related Pearce-Kaye-Hall signals in basolateral amygdala require the midbrain dopaminergic system. Biol Psychiatry. 2012; 72(12):1012-9. PMC: 3465645. DOI: 10.1016/j.biopsych.2012.05.023. View

Kuypers K, Wingen M, Heinecke A, Formisano E, Ramaekers J . MDMA intoxication and verbal memory performance: a placebo-controlled pharmaco-MRI study. J Psychopharmacol. 2011; 25(8):1053-61. DOI: 10.1177/0269881111405361. View

Feduccia A, Mithoefer M . MDMA-assisted psychotherapy for PTSD: Are memory reconsolidation and fear extinction underlying mechanisms?. Prog Neuropsychopharmacol Biol Psychiatry. 2018; 84(Pt A):221-228. DOI: 10.1016/j.pnpbp.2018.03.003. View

Jerome L, Feduccia A, Wang J, Hamilton S, Yazar-Klosinski B, Emerson A . Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials. Psychopharmacology (Berl). 2020; 237(8):2485-2497. PMC: 7351848. DOI: 10.1007/s00213-020-05548-2. View

Douglas Bremner J, Gurel N, Jiao Y, Wittbrodt M, Levantsevych O, Huang M . Transcutaneous vagal nerve stimulation blocks stress-induced activation of Interleukin-6 and interferon-γ in posttraumatic stress disorder: A double-blind, randomized, sham-controlled trial. Brain Behav Immun Health. 2021; 9:100138. PMC: 8474180. DOI: 10.1016/j.bbih.2020.100138. View

Kirkpatrick M, Baggott M, Mendelson J, Galloway G, Liechti M, Hysek C . MDMA effects consistent across laboratories. Psychopharmacology (Berl). 2014; 231(19):3899-905. PMC: 4161650. DOI: 10.1007/s00213-014-3528-z. View

10.

Koenigs M, Huey E, Raymont V, Cheon B, Solomon J, Wassermann E . Focal brain damage protects against post-traumatic stress disorder in combat veterans. Nat Neurosci. 2007; 11(2):232-7. PMC: 2693133. DOI: 10.1038/nn2032. View

11.

Bouso J, Doblin R, Farre M, Alcazar M, Gomez-Jarabo G . MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder. J Psychoactive Drugs. 2008; 40(3):225-36. DOI: 10.1080/02791072.2008.10400637. View

12.

Gurel N, Wittbrodt M, Jung H, Shandhi M, Driggers E, Ladd S . Transcutaneous cervical vagal nerve stimulation reduces sympathetic responses to stress in posttraumatic stress disorder: A double-blind, randomized, sham controlled trial. Neurobiol Stress. 2020; 13:100264. PMC: 7739181. DOI: 10.1016/j.ynstr.2020.100264. View

13.

Baumann M, Rothman R . Neural and cardiac toxicities associated with 3,4-methylenedioxymethamphetamine (MDMA). Int Rev Neurobiol. 2009; 88:257-96. PMC: 3153986. DOI: 10.1016/S0074-7742(09)88010-0. View

14.

Carhart-Harris R, Murphy K, Leech R, Erritzoe D, Wall M, Ferguson B . The Effects of Acutely Administered 3,4-Methylenedioxymethamphetamine on Spontaneous Brain Function in Healthy Volunteers Measured with Arterial Spin Labeling and Blood Oxygen Level-Dependent Resting State Functional Connectivity. Biol Psychiatry. 2014; 78(8):554-62. PMC: 4578244. DOI: 10.1016/j.biopsych.2013.12.015. View

15.

Bershad A, Mayo L, Van Hedger K, McGlone F, Walker S, de Wit H . Effects of MDMA on attention to positive social cues and pleasantness of affective touch. Neuropsychopharmacology. 2019; 44(10):1698-1705. PMC: 6785008. DOI: 10.1038/s41386-019-0402-z. View

16.

BLAKE D, Weathers F, Nagy L, Kaloupek D, Gusman F, Charney D . The development of a Clinician-Administered PTSD Scale. J Trauma Stress. 1995; 8(1):75-90. DOI: 10.1007/BF02105408. View

17.

Barone W, Beck J, Mitsunaga-Whitten M, Perl P . Perceived Benefits of MDMA-Assisted Psychotherapy beyond Symptom Reduction: Qualitative Follow-Up Study of a Clinical Trial for Individuals with Treatment-Resistant PTSD. J Psychoactive Drugs. 2019; 51(2):199-208. DOI: 10.1080/02791072.2019.1580805. View

18.

Mithoefer M, Mithoefer A, Feduccia A, Jerome L, Wagner M, Wymer J . 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. Lancet Psychiatry. 2018; 5(6):486-497. DOI: 10.1016/S2215-0366(18)30135-4. View

19.

Oehen P, Traber R, Widmer V, Schnyder U . A randomized, controlled pilot study of MDMA (± 3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD). J Psychopharmacol. 2012; 27(1):40-52. DOI: 10.1177/0269881112464827. View

20.

Lamb D, Porges E, Lewis G, Williamson J . Non-invasive Vagal Nerve Stimulation Effects on Hyperarousal and Autonomic State in Patients with Posttraumatic Stress Disorder and History of Mild Traumatic Brain Injury: Preliminary Evidence. Front Med (Lausanne). 2017; 4:124. PMC: 5534856. DOI: 10.3389/fmed.2017.00124. View